Open AccessIn vitro activity of BAY v 3522, a new cephalosporin for oral administration
Author(s) -
Teri L. Hodges,
George M. Eliopoulos,
Karin Klimm,
Robert C. Moellering
Publication year - 1990
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.34.9.1849
Subject(s) - cefaclor , cefuroxime , cefixime , cephradine , ciprofloxacin , cephalosporin , bay , amoxicillin , cefdinir , ampicillin , cefadroxil , antibiotics , medicine , erythromycin , microbiology and biotechnology , biology , civil engineering , engineering
The activity of BAY v 3522 was tested against over 500 clinical bacterial isolates and compared with the activities of ampicillin, amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, and/or ciprofloxacin, erythromycin, and metronidazole. BAY v 3522 activity against staphylococci and streptococci equaled or exceeded those of the other agents. BAY v 3522 exhibited no significant advantage over cefaclor, cefuroxime, or cephalexin against gram-negative bacilli.